These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31531499)

  • 1. High-content screening Raman spectroscopy (HCS-RS) of panitumumab-exposed colorectal cancer cells.
    Mondol AS; El-Mashtoly SF; Frick T; Gerwert K; Popp J; Schie IW
    Analyst; 2019 Oct; 144(20):6098-6107. PubMed ID: 31531499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Throughput Screening Raman Spectroscopy Platform for Label-Free Cellomics.
    Schie IW; Rüger J; Mondol AS; Ramoji A; Neugebauer U; Krafft C; Popp J
    Anal Chem; 2018 Feb; 90(3):2023-2030. PubMed ID: 29286634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
    Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
    Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
    Pietrantonio F; Cremolini C; Aprile G; Lonardi S; Orlandi A; Mennitto A; Berenato R; Antoniotti C; Casagrande M; Marsico V; Marmorino F; Cardellino GG; Bergamo F; Tomasello G; Formica V; Longarini R; Giommoni E; Caporale M; Di Bartolomeo M; Loupakis F; de Braud F
    Oncologist; 2015 Nov; 20(11):1261-5. PubMed ID: 26446234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells.
    El-Mashtoly SF; Yosef HK; Petersen D; Mavarani L; Maghnouj A; Hahn S; Kötting C; Gerwert K
    Anal Chem; 2015 Jul; 87(14):7297-304. PubMed ID: 26075314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
    Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
    Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
    Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH
    J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Fakih MG; Knox HN; Maglinte GA; Hjelmgren J; Barber B; Schwartzberg LS
    J Med Econ; 2015; 18(8):619-28. PubMed ID: 25822327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrimination of serum Raman spectroscopy between normal and colorectal cancer using selected parameters and regression-discriminant analysis.
    Li X; Yang T; Li S
    Appl Opt; 2012 Jul; 51(21):5038-43. PubMed ID: 22858942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging vs Nonimaging Raman Spectroscopy for High-Throughput Single-Cell Phenotyping.
    Hobro AJ; Pavillon N; Koike K; Sugiyama T; Umakoshi T; Verma P; Fujita K; Smith NI
    Anal Chem; 2024 May; 96(18):7047-7055. PubMed ID: 38653469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine.
    Baba Y; Tamura T; Satoh Y; Gotou M; Sawada H; Ebara S; Shibuya K; Soeda J; Nakamura K
    Mol Oncol; 2017 Aug; 11(8):1065-1077. PubMed ID: 28486761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single cell Raman spectroscopy for cell sorting and imaging.
    Li M; Xu J; Romero-Gonzalez M; Banwart SA; Huang WE
    Curr Opin Biotechnol; 2012 Feb; 23(1):56-63. PubMed ID: 22138495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic evaluation of the biological variance within the Raman based colorectal tissue diagnostics.
    Vogler N; Bocklitz T; Subhi Salah F; Schmidt C; Bräuer R; Cui T; Mireskandari M; Greten FR; Schmitt M; Stallmach A; Petersen I; Popp J
    J Biophotonics; 2016 May; 9(5):533-41. PubMed ID: 26687775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of panitumumab for K-ras wild-type unresectable or recurrent colorectal cancer - a study focusing on first-line treatment].
    Mitomo S; Suto T; Umemura A; Ishida K; Kanno K; Takeda D; Fujita T; Otsuka K; Nitta H; Uesugi N; Sugai T; Wakabayashi G
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):731-5. PubMed ID: 25129084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
    Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimisation of wavelength modulated Raman spectroscopy: towards high throughput cell screening.
    Praveen BB; Mazilu M; Marchington RF; Herrington CS; Riches A; Dholakia K
    PLoS One; 2013; 8(6):e67211. PubMed ID: 23825643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual staining of colon cancer tissue by label-free Raman micro-spectroscopy.
    Petersen D; Mavarani L; Niedieker D; Freier E; Tannapfel A; Kötting C; Gerwert K; El-Mashtoly SF
    Analyst; 2017 Apr; 142(8):1207-1215. PubMed ID: 27840868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
    Peeters M; Oliner KS; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; He P; Yu H; Koukakis R; Terwey JH; Jung AS; Sidhu R; Patterson SD
    Clin Cancer Res; 2015 Dec; 21(24):5469-79. PubMed ID: 26341920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell Raman sorting.
    Li M; Boardman DG; Ward A; Huang WE
    Methods Mol Biol; 2014; 1096():147-53. PubMed ID: 24515367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Raman spectroscopic study of cell response to clinical doses of ionizing radiation.
    Harder SJ; Matthews Q; Isabelle M; Brolo AG; Lum JJ; Jirasek A
    Appl Spectrosc; 2015; 69(2):193-204. PubMed ID: 25588147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.